Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
Rhea-AI Summary
Sight Sciences (Nasdaq: SGHT) provided preliminary, unaudited Q4 and full-year 2025 financial highlights for the period ended December 31, 2025. Q4 2025 revenue is expected to be $20.3M–$20.4M (≈+7% at midpoint). Full-year 2025 revenue is expected to be $77.3M–$77.4M (≈-3% at midpoint). Q4 Dry Eye revenue is ~$0.7M (+~130% YoY); full-year Dry Eye revenue is ~$1.6M vs $4.0M in 2024. Cash and cash equivalents were approximately $92M at Dec 31, 2025; cash used in 2025 totaled ~$28M. Results are preliminary and subject to audit with final results expected in March 2026.
Positive
- Q4 revenue +7% at midpoint
- Q4 Dry Eye revenue +130% year-over-year
- Cash balance approximately $92M at Dec 31, 2025
- Operational discipline: cash used Q4 ~$0.4M
Negative
- Full-year revenue down ~3% at midpoint
- Full-year Dry Eye revenue $1.6M versus $4.0M in 2024
- Results are preliminary and unaudited, subject to revision
News Market Reaction
On the day this news was published, SGHT declined 7.83%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.4% during that session. Argus tracked a trough of -8.7% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $31M from the company's valuation, bringing the market cap to $370M at that time. Trading volume was elevated at 2.4x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SGHT was up 3.2% pre-announcement while peers were mixed: BSGM +39.91%, CVRX -9.31%, ARAY -1.39%, MGRM -1.64%, and ELMD +0.24%, pointing to stock-specific drivers rather than a broad medical devices move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 11 | Clinical data update | Positive | +8.0% | Peer-reviewed OMNI data showing durable IOP and medication reductions. |
| Nov 06 | Quarterly earnings | Positive | -0.6% | Q3 results and raised 2025 revenue and expense guidance. |
| Nov 06 | Leadership changes | Neutral | -0.6% | Appointment of new COO and CFO to support growth strategy. |
| Nov 04 | Investor conferences | Neutral | +1.0% | Participation in two healthcare investor conferences with webcasts. |
| Oct 23 | Earnings call notice | Neutral | +1.3% | Announcement of Q3 2025 earnings release and conference call details. |
Recent news has more often seen price moves align modestly with the underlying news tone, with only one clear divergence on a positive earnings/guidance update.
Over the last several months, Sight Sciences has combined operational tightening with mixed top-line trends. On Mar 5, 2025, it reported modest 2024 growth and guided 2025 revenue lower amid Medicare LCD pressures, followed by Q1–Q3 2025 results showing revenue declines but consistently high gross margins and lower operating expenses. Guidance was raised in Q2 and again in Q3, and leadership changes including a new COO and CFO were announced in November 2025. The current preliminary 2025 update fits into this pattern of disciplined cost control, evolving Dry Eye reimbursement, and stabilizing Surgical Glaucoma revenue.
Market Pulse Summary
The stock moved -7.8% in the session following this news. A negative reaction despite signs of Q4 revenue growth would fit a pattern where markets focus on full‑year declines and cash usage. Preliminary 2025 revenue of about $77.3M–$77.4M implies a modest YoY contraction, and Dry Eye revenue for the year remains well below 2024 at roughly $1.6M. With about $92M in cash and approximately $28M used during 2025, concerns about the pace of improvement or the unaudited nature of these figures could have amplified selling pressure.
Key Terms
medicare administrative contractor regulatory
gaap financial
internal control over financial reporting regulatory
AI-generated analysis. Not financial advice.
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2025.
Select Preliminary Financial Highlights
Fourth quarter 2025 total revenue is expected to be in the range of
- Surgical Glaucoma revenues are expected to be in the range of
$19.6 million to$19.7 million , an increase of5% at the estimated midpoint compared to the prior year period.
- Dry Eye revenues are expected to be approximately
$0.7 million , an increase of approximately130% compared to the prior year period.
Full year 2025 total revenue is expected to be in the range of
- Surgical Glaucoma revenues are expected to be in the range of
$75.6 million to$75.7 million , flat at the estimated midpoint compared to the prior year.
- Dry Eye revenues are expected to be approximately
$1.6 million , compared to$4.0 million in 2024.
The Company’s cash and cash equivalents as of December 31, 2025, were approximately
- Cash used in the quarter totaled approximately
$0.4 million , reflecting continued operational discipline.
- Cash used during the year totaled approximately
$28 million .
“We are pleased with our progress in the fourth quarter, including approximately
The Company’s fourth quarter and full year 2025 preliminary, unaudited financial results included in this press release have been prepared by management and are based on information currently available to management and subject to the completion of the Company’s 2025 audit. The Company expects to announce complete fourth quarter and full year 2025 financial results in March 2026.
Financial Disclosure Advisory
The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). The select preliminary, unaudited results described in this press release are estimates only and are subject to revision until the Company reports its full financial and business results for the fourth quarter and full year 2025. These estimates are not a comprehensive statement of the Company’s financial results for the fourth quarter and full year 2025 and actual results may differ materially from these estimates as a result of the completion of year-end accounting procedures and adjustments, including the execution of the Company’s internal control over financial reporting, the completion of the preparation and audit of the Company’s financial statements and the subsequent occurrence or identification of events prior to the formal issuance of the audited financial statements for the full year 2025.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2026 Sight Sciences. All rights reserved.
Forward-Looking Statements
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with such safe harbor provisions. Any statements made in this press release or during the earnings call that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, but are not limited to, statements concerning expected financial and business results for fourth quarter and full year 2025; the Company’s confidence in its growth outlook, operational discipline, and path toward cash flow breakeven without requiring additional equity capital; and timing for announcement of complete fourth quarter and full year 2025 financial and business results. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
Media contact:
pr@SightSciences.com
FAQ
What preliminary revenue did Sight Sciences (SGHT) report for Q4 2025?
How did Sight Sciences' Dry Eye revenue perform in Q4 and full-year 2025 (SGHT)?
What is Sight Sciences' cash position as of Dec 31, 2025 (SGHT)?
Are Sight Sciences' Q4 and full-year 2025 results final (SGHT)?
How did Surgical Glaucoma revenue trend in 2025 for SGHT?
What does the SGHT cash usage in Q4 2025 indicate for investors?
